We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Silgan Unicep

First POC Hepatitis C RNA Test Enables Single-Visit Testing and Treatment

By LabMedica International staff writers
Posted on 28 Jun 2024
Image: The U.S. FDA has granted marketing authorization for the Xpert HCV test together with the GeneXpert Xpress System (Photo courtesy of Cepheid)
Image: The U.S. FDA has granted marketing authorization for the Xpert HCV test together with the GeneXpert Xpress System (Photo courtesy of Cepheid)

Hepatitis C, a liver infection caused by the hepatitis C virus (HCV), spreads through contact with the blood of an infected person. While some individuals may experience a short-term illness, over half of those infected develop a chronic, long-term condition. In the United States, it is estimated that between 2.4 and 4 million people are living with hepatitis C. If untreated, the virus can lead to severe health issues, including liver cancer and liver failure. Until now, HCV testing has involved multiple steps, requiring patients to return for results and further tests, often resulting in missed diagnoses and treatment. Now, a breakthrough has been made with the introduction of the first point-of-care HCV test, which facilitates testing and treatment in a single visit for those at risk.

Developed by Cepheid (Sunnyvale, CA, USA), the Xpert HCV test eliminates the need to send samples to a central lab and can detect HCV RNA from a fingertip blood sample, delivering results within approximately one hour. The U.S. Food and Drug Administration has granted marketing authorization for the use of the Xpert HCV test alongside the GeneXpert Xpress System. This test is authorized for use in various settings under a CLIA (Clinical Laboratory Improvement Amendments) Certificate of Waiver, including substance use disorder treatment centers, correctional facilities, syringe service programs, physician's offices, emergency departments, and urgent care clinics. This significant development supports a test-and-treat approach, allowing individuals to be tested and, if they test positive for HCV RNA, to be connected to care and potentially begin treatment during the same healthcare visit.

"Despite the existence of a safe and highly effective oral cure for hepatitis C, many people do not know they have the disease due partly to the lack of availability of convenient, widespread testing options," said Jeff Shuren, M.D., J.D., director of the FDA's Center for Devices and Radiological Health. "Equipping health care providers with tools to diagnose and treat patients in the same visit can result in hundreds of thousands more hepatitis C patients being diagnosed and treated, preventing individual disease progression and additional spread of the virus."


New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Latest Molecular Diagnostics News

Early Detection of miRNAs in Maternal Blood Could Predict Preeclampsia

New Analytical Tool Could Replace Traditional Biopsies with Liquid Biopsies for Disease Diagnosis

Multiplex PCR Test Detects Common Viral and Bacterial Causes of Respiratory or Sore Throat Infections in 15 Minutes